Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)

被引：0
|
作者：
Rini, B., I
Escudier, B.
Tomczak, P.
机构：
来源：
LANCET | 2012年 / 380卷 / 9856期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1818 / 1818
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Rini, Brian I.
    Escudier, Bernard
    Tomczak, Piotr
    Kaprin, Andrey
    Szczylik, Cezary
    Hutson, Thomas E.
    Michaelson, M. Dror
    Gorbunova, Vera A.
    Gore, Martin E.
    Rusakov, Igor G.
    Negrier, Sylvie
    Ou, Yen-Chuan
    Castellano, Daniel
    Lim, Ho Yeong
    Uemura, Hirotsugu
    Tarazi, Jamal
    Cella, David
    Chen, Connie
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert J.
    LANCET, 2011, 378 (9807): : 1931 - 1939
  • [2] Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
    Kenney, Patrick A.
    Wood, Christopher G.
    EUROPEAN UROLOGY, 2012, 62 (01) : 182 - 183
  • [3] Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (02): : 412 - 413
  • [4] Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma
    不详
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2012, 1 (01) : 11 - 12
  • [5] Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
    B Escudier
    M D Michaelson
    R J Motzer
    T E Hutson
    J I Clark
    H Y Lim
    E Porfiri
    P Zalewski
    G Kannourakis
    M Staehler
    J Tarazi
    B Rosbrook
    L Cisar
    S Hariharan
    S Kim
    B I Rini
    British Journal of Cancer, 2014, 110 : 2821 - 2828
  • [6] Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
    Escudier, B.
    Michaelson, M. D.
    Motzer, R. J.
    Hutson, T. E.
    Clark, J. I.
    Lim, H. Y.
    Porfiri, E.
    Zalewski, P.
    Kannourakis, G.
    Staehler, M.
    Tarazi, J.
    Rosbrook, B.
    Cisar, L.
    Hariharan, S.
    Kim, S.
    Rini, B. I.
    BRITISH JOURNAL OF CANCER, 2014, 110 (12) : 2821 - 2828
  • [7] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (vol 14, pg 552, 2013)
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    LANCET ONCOLOGY, 2013, 14 (07): : E254 - E254
  • [8] PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS
    Uemura, H.
    Ou, Y. -C.
    Lim, H. Y.
    Tomita, Y.
    Ueda, T.
    Menon, H.
    Chung, J.
    Guo, J.
    Tarazi, J.
    Kim, S.
    Naito, S.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 6 - 6
  • [9] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    Motzer, Robert J.
    Escudier, Bernard
    Tomczak, Piotr
    Hutson, Thomas E.
    Michaelson, M. Dror
    Negrier, Sylvie
    Oudard, Stephane
    Gore, Martin E.
    Tarazi, Jamal
    Hariharan, Subramanian
    Chen, Connie
    Rosbrook, Brad
    Kim, Sinil
    Rini, Brian I.
    LANCET ONCOLOGY, 2013, 14 (06): : 552 - 562
  • [10] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
    Hutson, Thomas E.
    Lesovoy, Vladimir
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Bair, Angel H.
    Rosbrook, Brad
    Chen, Connie
    Kim, Sinil
    Vogelzang, Nicholas J.
    LANCET ONCOLOGY, 2013, 14 (13): : 1287 - 1294
12345